Rhythm Pharmaceuticals (RYTM) Competitors $55.21 +2.92 (+5.58%) Closing price 04:00 PM EasternExtended Trading$55.22 +0.01 (+0.02%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RYTM vs. VTRS, RDY, SRPT, PCVX, QGEN, ASND, ROIV, LNTH, RVMD, and LEGNShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Rhythm Pharmaceuticals vs. Viatris Dr. Reddy's Laboratories Sarepta Therapeutics Vaxcyte Qiagen Ascendis Pharma A/S Roivant Sciences Lantheus Revolution Medicines Legend Biotech Rhythm Pharmaceuticals (NASDAQ:RYTM) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Do institutionals & insiders hold more shares of RYTM or VTRS? 79.9% of Viatris shares are held by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer RYTM or VTRS? Rhythm Pharmaceuticals received 280 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 67.63% of users gave Rhythm Pharmaceuticals an outperform vote while only 34.85% of users gave Viatris an outperform vote. CompanyUnderperformOutperformRhythm PharmaceuticalsOutperform Votes30367.63% Underperform Votes14532.37% ViatrisOutperform Votes2334.85% Underperform Votes4365.15% Which has more risk & volatility, RYTM or VTRS? Rhythm Pharmaceuticals has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500. Comparatively, Viatris has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Is RYTM or VTRS more profitable? Viatris has a net margin of -5.87% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Viatris' return on equity of 16.46% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-230.07% -367.36% -77.47% Viatris -5.87%16.46%7.09% Does the media prefer RYTM or VTRS? In the previous week, Viatris had 7 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 19 mentions for Viatris and 12 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.59 beat Viatris' score of 0.04 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 4 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Neutral Which has stronger valuation & earnings, RYTM or VTRS? Viatris has higher revenue and earnings than Rhythm Pharmaceuticals. Viatris is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M26.82-$184.68M-$4.35-12.69Viatris$14.74B0.76$54.70M-$0.53-17.77 Do analysts recommend RYTM or VTRS? Rhythm Pharmaceuticals presently has a consensus price target of $69.46, indicating a potential upside of 25.81%. Viatris has a consensus price target of $10.50, indicating a potential upside of 11.46%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Rhythm Pharmaceuticals is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92Viatris 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 SummaryRhythm Pharmaceuticals and Viatris tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.49B$7.11B$5.73B$8.12BDividend YieldN/A2.77%4.41%4.09%P/E Ratio-12.756.3224.4819.28Price / Sales26.82237.41402.1289.09Price / CashN/A65.6738.1134.64Price / Book19.246.626.904.38Net Income-$184.68M$141.83M$3.18B$247.04M7 Day Performance7.58%0.44%0.81%2.01%1 Month Performance-4.81%-7.39%0.40%-8.31%1 Year Performance41.13%-4.69%13.84%5.72% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals4.3764 of 5 stars$55.21+5.6%$69.46+25.8%+28.8%$3.49B$130.13M-12.75140Analyst ForecastInsider TradeNews CoverageVTRSViatris2.2025 of 5 stars$9.50-0.3%$10.50+10.5%-19.0%$11.34B$14.74B-12.8437,000RDYDr. Reddy's Laboratories2.9799 of 5 stars$12.70-1.7%$17.00+33.9%-11.5%$10.60B$311.31B20.2124,800News CoverageGap UpSRPTSarepta Therapeutics4.6909 of 5 stars$99.69-3.2%$170.41+70.9%-40.7%$9.67B$1.90B79.751,314News CoveragePCVXVaxcyte2.3938 of 5 stars$68.89-3.2%$147.50+114.1%+9.8%$8.87BN/A-14.98160Positive NewsQGENQiagen4.0777 of 5 stars$38.93-2.1%$47.71+22.6%-7.4%$8.64B$1.98B108.405,967Short Interest ↓Positive NewsASNDAscendis Pharma A/S2.1216 of 5 stars$138.18-5.2%$202.36+46.4%+12.0%$8.39B$363.64M-19.461,017Analyst ForecastNews CoverageROIVRoivant Sciences2.1927 of 5 stars$10.58-0.6%$18.08+70.9%+8.5%$7.55B$122.59M-70.53860News CoveragePositive NewsLNTHLantheus4.6756 of 5 stars$110.01+3.5%$132.86+20.8%+80.9%$7.53B$1.53B18.30700Insider TradeShort Interest ↓Positive NewsRVMDRevolution Medicines4.2753 of 5 stars$36.82-6.1%$66.31+80.1%+23.3%$6.85B$742,000.00-10.26250Insider TradeNews CoveragePositive NewsLEGNLegend Biotech2.031 of 5 stars$34.03-3.5%$79.50+133.6%-41.4%$6.22B$520.18M-35.821,800Analyst ForecastAnalyst RevisionNews Coverage Remove Ads Related Companies and Tools Related Companies Viatris Competitors Dr. Reddy's Laboratories Competitors Sarepta Therapeutics Competitors Vaxcyte Competitors Qiagen Competitors Ascendis Pharma A/S Competitors Roivant Sciences Competitors Lantheus Competitors Revolution Medicines Competitors Legend Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RYTM) was last updated on 3/19/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RYTM Stock Alerts